Painful painkillers
Notwithstanding the nature of the verdicts emanating from both the European and US regulatory offices during the last week over the fate of Cox-2 inhibitors, drug manufacturers who have existing products or are likely to introduce variants in the same class, are putting up a stoical front.

Clinical trials: Will the boom sustain?
Pharma MNCs and CROs have been able to conduct good quality clinical trials in India despite several hurdles because of availability of professionals and their willingness to comply with regulations and standards in true spirit, says Sanjay Gupta